HCPCS code J1559: Hizentra injection billing and coding guide

Key Takeaways

HCPCS code J1559 describes injection, immune globulin (Hizentra), 100 mg, a subcutaneous immunoglobulin used for primary immunodeficiency and CIDP.

J1559 is classified by CMS as a single-dose container code, making JW and JZ wastage modifiers applicable when reporting drug waste or confirming no waste.

Medicare coverage for J1559 is governed by CMS Article A57778; providers must link the claim to a supported ICD-10-CM diagnosis with documentation meeting LCD requirements.

Pabau’s claims management software connects J1559 charge capture to clinical documentation, reducing modifier errors and supporting audit-ready records for infusion practices.

HCPCS code J1559 describes injection, immune globulin (Hizentra), 100 mg. It is a Level II HCPCS code maintained by CMS under “Drugs Administered Other than Oral Method,” billed for Hizentra, a 20% subcutaneous immunoglobulin (SCIg) product manufactured by CSL Behring.

This guide covers the JW/JZ modifier rules, NDC crosswalk, Medicare coverage criteria, and documentation standards that determine whether a J1559 claim is paid, along with how the code differs from related immune globulin J-codes when a patient moves between IV and subcutaneous therapy.

HCPCS code J1559: Description and clinical context

Clinically, Hizentra carries FDA approval for two primary indications. The first is primary immunodeficiency (PI), covering conditions such as common variable immunodeficiency (CVID), X-linked agammaglobulinemia, and combined immunodeficiencies. The second is chronic inflammatory demyelinating polyneuropathy (CIDP), where subcutaneous immunoglobulin maintenance therapy has demonstrated efficacy in preventing relapse following intravenous induction.

Hizentra is administered via subcutaneous infusion, typically by the patient at home or in a clinical infusion setting. When a home infusion provider bills separately for the nursing visit rather than only the drug, that per-diem service is reported under HCPCS code S9500 (home infusion therapy service), distinct from the drug charge captured by J1559.

Practices running an integrated claims management platform that ties charge capture to drug administration records have a structural advantage here. When the administered dose, diagnosis code, and HCPCS code all flow from the same clinical encounter record, the risk of mismatched claim data drops substantially.

The billing unit for J1559 is 100 mg. For a patient who receives 1,200 mg in a weekly subcutaneous session, the claim would report 12 units of J1559. Dose verification against the patient’s weight-based prescription is a standard audit target, so chart documentation of the prescribed and administered dose must be explicit.

Medicare coverage and reimbursement for HCPCS code J1559

Medicare Part B covers Hizentra (J1559) when billed incident to a physician’s service or under the buy-and-bill model for infusion administered in a clinical setting. Reimbursement follows the Medicare Part B drug payment methodology, which uses the Average Sales Price (ASP) plus 6% for most covered drugs.

Practices relying on IV therapy clinic management platforms that pull current ASP data reduce the risk of billing below actual acquisition cost.

CMS updates ASP-based payment limits quarterly. The CMS Physician Fee Schedule lookup tool provides the current payment amounts for J1559 by MAC jurisdiction. Because rates change each quarter, coders should verify current amounts before finalizing fee schedules for infusion services, rather than relying on cached figures from prior quarters.

Coverage authority for immune globulin products including J1559 falls under CMS Medicare Coverage Database Article A57778. This article governs billing and coding for both subcutaneous and intravenous immune globulin formulations under Medicare Part B.

A key provision: it is the provider’s responsibility to select codes to the highest level of specificity from the ICD-10-CM code book appropriate to the year in which the service is rendered.

Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors (MACs) such as Novitas Solutions also apply. These LCDs specify which ICD-10-CM diagnosis codes support medical necessity for immune globulin therapy. Claims submitted without a covered diagnosis code, or where the medical record does not substantiate the diagnosis, are the primary driver of J1559 denials.

• Covered diagnoses (commonly supported): Primary immunodeficiency disorders (ICD-10-CM D80-D83), CIDP (G61.81), and secondary immunodeficiencies in select clinical contexts
• Prior authorization: Required by many commercial payers and some Medicaid programs; not uniformly required under Medicare Part B but MAC pre-authorization policies vary
• Place of service: Office (11), infusion center (22), or home (12) depending on administration setting; affects payment rate under certain payer contracts
• ASP update frequency: Quarterly; consult the CMS fee schedule before submitting claims in a new quarter

For commercial payers and Medicaid, reimbursement rates and coverage criteria vary by plan and state. Blanket assumptions about Medicare Part B rules should never be applied to commercial claims without verifying the specific payer’s drug coverage policy.

JW and JZ modifier requirements for J1559

CMS has formally designated J1559 (Hizentra) as a single-dose container product. That classification triggers specific wastage reporting rules that apply whenever the full contents of a single-dose container – vial or prefilled syringe – are not administered. Getting these modifiers wrong is one of the fastest routes to a billing compliance issue.

The CMS HCPCS Level II coding system sets out these rules, and CMS has published a dedicated JW Modifier and JZ Modifier Policy HCPCS Codes document that lists J1559 explicitly as a code to which both modifiers apply.

Here is how the two modifiers function in practice for J1559 claims:

• JW modifier (drug amount discarded or not administered to any patient): Appended to a separate line item reporting the units of Hizentra that were drawn but not administered. The discarded amount is billable under Medicare Part B when reported with JW. Required when any content from a single-dose container is wasted and not transferred to another patient.
• JZ modifier (zero drug waste): Appended to the administered dose line when no drug was wasted. Its purpose is affirmative confirmation that the full administered amount equaled the full container content, and that no waste occurred. Introduced by CMS to reduce wastage billing abuse and provide clearer audit trails.

A common scenario: a patient is prescribed 800 mg of Hizentra per weekly dose. CSL Behring discontinued single-dose vial packaging for the US market by the end of September 2024, so Hizentra is now supplied exclusively as prefilled syringes in 1g, 2g, 4g, and 10g sizes. The practice uses a 1g (1,000 mg) prefilled syringe.

Eight units of J1559 (800 mg) are administered, and the remaining 200 mg (2 units) are discarded. The claim reports 8 units of J1559 on one line – JZ would be incorrect here, since waste occurred – plus 2 units of J1559 appended with the JW modifier for the discarded amount.

Practices running mobile IV therapy business operations or in-practice infusion services should ensure their billing platform can capture waste amounts at the point of administration, not as a retrospective calculation. The documentation supporting the JW modifier must include the administered dose, the container size used, and explicit notation of the discarded volume.

NDC to HCPCS crosswalk for J1559

Many payers and pharmacy benefit managers require the National Drug Code (NDC) to be reported alongside J1559. The NDC identifies the specific Hizentra product and package size dispensed.

CSL Behring discontinued single-dose vial packaging for the US market in September 2024; Hizentra is now supplied as prefilled syringes in four sizes – 1g, 2g, 4g, and 10g – each carrying a distinct NDC number.

The NDC must be reported in the correct format on the claim: 11-digit format, units in metric decimal quantity, and unit qualifier GR (grams) or ML (milliliters) as required by the specific payer.

Crosswalk verification tools can match the specific Hizentra NDC to J1559, but the mapping should be verified against current NDC data because product NDCs can change with packaging updates or manufacturer revisions.

For practices using prescription management workflows integrated with their billing platform, NDC capture at the point of drug dispensing feeds directly into the claim, reducing manual transcription errors that commonly trigger NDC-related denials.

Connect your J1559 billing to your clinical workflow

Pabau helps infusion and immunology practices capture drug administration data, apply the correct HCPCS codes, and submit audit-ready claims without manual rework between the clinical and billing teams.

Book a demo

Documentation requirements for J1559 (Hizentra) billing

Weak documentation is the underlying cause of most J1559 claim denials at audit. The clinical record must support the diagnosis, the medical necessity of subcutaneous immune globulin therapy, the specific product and lot number, the dose administered, and any drug waste. That is not a short list, and each element serves a distinct audit function.

Practices following IV therapy clinic best practices typically structure their administration records to capture all of these elements at the point of care. Retrofitting documentation after a denial notice is both time-consuming and, in audit situations, insufficient if the contemporaneous record is thin.

The key documentation elements for a defensible J1559 claim are:

• Confirmed diagnosis: The ICD-10-CM code on the claim must map to a diagnosis documented in the medical record, supported by clinical findings, lab values, or specialist assessment as appropriate for the condition
• Medical necessity justification: For primary immunodeficiency, documentation typically includes IgG levels, infection history, and immunologist oversight; our allergy and immunology consultation notes template shows the structure many practices use to capture this. For CIDP, documentation of intravenous induction followed by subcutaneous maintenance is standard.
• Prescription and dose order: A physician or qualified prescriber order specifying the product (Hizentra), dose in milligrams, frequency, and route
• Administration record: Date and time of administration, administered volume and dose in mg, lot number and expiration date, infusion site, name of the administering clinician, and any adverse reaction observed – see IV therapy complications for the reactions infusion teams should watch for
• Waste record: If JW modifier is applied, the record must document the container size used (vial or prefilled syringe), the amount administered, and the amount discarded, with a statement that the discarded amount was not transferred to another patient
• Prior authorization reference: Where prior authorization was obtained, the authorization number must be retained in the record and correlate with the claim dates and doses

Using digital intake forms that capture immune globulin-specific clinical data at the start of therapy creates a structured baseline record. As therapy progresses, each administration session adds to that baseline. At audit, the complete longitudinal record makes it straightforward to demonstrate that every J1559 claim was supported by contemporaneous clinical documentation.

Related HCPCS codes for immune globulin

J1559 is one of several HCPCS J-codes covering immune globulin products. Selecting the wrong code is a common error when a practice transitions a patient from intravenous to subcutaneous therapy, or when a formulary change substitutes one product for another. Each code is product-specific and not interchangeable.

For practices handling setting up an infusion clinic that administers multiple immune globulin products, maintaining a product-to-code mapping within the billing system prevents cross-code errors. A chart in the EHR or billing platform listing each stocked product alongside its HCPCS code and unit size reduces the risk at the point of charge entry.

The intravenous formulations in this table carry FDA-approved indications beyond primary immunodeficiency and CIDP. Gamunex-C/Gammaked (J1561) and Privigen (J1459) are also approved for chronic immune thrombocytopenic purpura (ICD-10 D69.3), which is not an approved use for subcutaneous Hizentra.

Other immune globulin products carry their own dedicated codes outside this core table, including Gammaplex (HCPCS code J1557). When a newer or reformulated product doesn’t yet have a permanent J-code, HCPCS code J3590 (unclassified biologics) can serve as a temporary placeholder, though payers typically require additional documentation to support pricing on that code.

The unit size difference between J1559 (100 mg per unit) and the intravenous codes (500 mg per unit) is a frequent source of billing errors during product transitions, and gram-for-gram unit math is not the only conversion at issue when a patient switches from IVIG to Hizentra.

Hizentra’s FDA-approved prescribing information requires a dose-adjustment factor for that switch: the initial subcutaneous dose equals the previous IGIV dose in grams multiplied by 1.37, to offset lower bioavailability with subcutaneous dosing.

A patient switching from 25g of IVIG billed as 50 units of J1561 (50 x 500 mg) would need an initial Hizentra dose of approximately 34.25g (25g x 1.37) – roughly 342 to 343 units of J1559 (100 mg each), not the 250 units a straight gram-for-gram conversion would suggest.

Applying the wrong conversion factor when transitioning a patient from IVIG to SCIg therapy creates a mismatch between the prescribed dose and the billed amount, which is exactly the kind of discrepancy a payer’s claims system is built to flag.

Referencing IV therapy intake forms that record the specific product stocked and used for each patient, rather than generic “immune globulin” references, creates a clean audit trail that supports product-to-code accuracy. For further HCPCS code lookup support, the AAPC Codify HCPCS lookup tool provides searchable access to current code descriptors and crosswalk data.

Billing workflow for J1559 in clinical practice

Clean J1559 billing follows a predictable sequence. Each step in the workflow is a potential failure point, and practices that document each step systematically have significantly lower denial rates than those handling each element ad hoc.

Practices administering Hizentra through home infusion and specialty drug administration services should map their J1559 billing process against this sequence, assigning clear ownership for diagnosis verification, NDC capture, and modifier application at each step.

1. Verify diagnosis and coverage eligibility: Confirm the patient’s ICD-10-CM diagnosis is supported by the relevant MAC LCD and that their payer covers Hizentra for that indication. Check prior authorization requirements before the first administration session.
2. Confirm product and lot number at administration: Record the Hizentra product NDC, lot number, expiration date, container size (vial or prefilled syringe), and administered dose in the administration record at the time of infusion.
3. Calculate units: Divide the total milligrams administered by 100 to determine J1559 units. Calculate waste in milligrams and divide by 100 for JW units.
4. Apply JW or JZ modifier: If any drug was wasted, report administered units on one claim line and discarded units appended with JW on a separate line. If no waste occurred, append JZ to the administered units line.
5. Attach NDC if required: Check the payer’s NDC reporting requirement and format the NDC in the appropriate claim field (Box 24 on the CMS-1500 or the equivalent EDI segment).
6. Submit and track: Monitor the claim through your billing platform. Flag any denial reason code related to diagnosis mismatch, modifier error, or NDC issue for immediate review rather than routing to a generic denial queue.

For verification of current HCPCS code properties, the CMS HCPCS Level II code set (linked above) provides the authoritative code descriptions and annual update files, and the CMS Physician Fee Schedule (also linked above) provides current quarterly payment amounts for J1559 by geographic location.

Conclusion

Billing HCPCS code J1559 accurately depends on three things working together: the right product-to-code mapping, correct JW or JZ modifier application, and documentation that supports every element of the claim. Practices that treat these as separate concerns, rather than connected steps in a single workflow, generate the denials and audit risk that should have been preventable.

Pabau’s integrated clinical and billing platform gives infusion practices a structured way to connect drug administration records, charge capture, and claim submission in one place, reducing the manual handoffs where J1559 billing errors typically occur. To see how Pabau supports IV therapy practice growth through integrated billing and documentation, book a demo with the team.

Continue your research

Coding an intravenous immune globulin product? The HCPCS code J1561 (Gamunex/Gammaked) guide covers the 500 mg IVIG unit and the conversion math that matters when a patient transitions to subcutaneous Hizentra.

Tightening up your infusion documentation? IV therapy clinic best practices walks through capturing dose, lot number, and waste at the point of care so J1559 claims stay audit-ready.

Choosing a platform for an infusion practice? Our roundup of the best EMR for IV therapy compares systems that link charge capture, ASP pricing, and clinical records in one workflow.

Frequently asked questions